|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2318 Mill Rd |
Address2 | Suite 800 |
City | Alexandria |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105592-12
|
||||||||
|
6. House ID# 447380001
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Amanda Schwartz |
Date | 1/20/2022 3:18:42 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 315 - Medicare Sequester Moratorium Act - relief from Medicare sequester
HR 1332/ S 368 -Telehealth Modernization Act - permanent repeal of Medicare geographic and originating site restrictions
HR 1946/S 1873- Multi Cancer Early Detection Coverage and Screening Act - provide for Medicare coverage of multi-cancer early detection screening tests
HR 1577/S 596 - Treat and Reduce Obesity Act of 2021 - expands Medicare coverage of intensive behavioral therapy for obesity
HR 2347/S 2691 - Strengthening the Vaccines for Children Program Act of 2021 - ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program
S 1287 - REFUND Act of 2021 - provide refunds for certain single dose vial drugs
HR 2903/S 1512- CONNECT for Health Act of 2021 - expand access to telehealth services
HR 3173/S 3018- Improving Seniors Timely Access to Care Act of 2021- stablishes several requirements and standards relating to prior authorization processes under Medicare Advantage plans
HR 3447 - Permanency for Audio-Only Telehealth Act- expand accessibility to certain telehealth services under Medicare
HR 4110- Reducing Hereditary Cancer Act- provide hereditary cancer genetic testing
HR 3089/S 1544- Accelerating Kids' Access to Care Act- streamline enrollment under the Medicaid program of certain providers across State lines
HR 1978/S 912- Protecting Seniors Through Immunization Act of 2021- improve Medicare coverage of vaccinations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amanda |
Schwartz |
|
|
|
Kristin |
Stuart |
|
|
|
Kristine |
Rufener |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S 464/HR 2163 Safe Step Act - implementing safe guards around step therapy (fail first) programs in ERISA regulated plans
HR 1550 - PREVENT HPV Cancers Act of 2021
HR 3258 - TACT Act of 2021- improve patient access to anti-cancer oral medications
S 610- Dr. Lorna Breen Health Care Provider Protection Act- address behavioral health and well-being among health care professionals
HR 4385/S 3080- Cancer Drug Parity Act of 2021- oral parity
HR 5801- HELP Copays Act- copay accumulator programs
S 3039/HR 2503- Social Determinants Accelerator Act of 2021- SDOH
HR 5030/S 2706- DIVERSE Trials Act- access to clinical trials
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amanda |
Schwartz |
|
|
|
Kristin |
Stuart |
|
|
|
Kristine |
Rufener |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
oppose S 438 - Traditional Cigar Manufacturing and Jobs Act
support HR 2125 - Quit Because of COVID-19 Act - provide coverage of comprehensive tobacco cessation services under such titles
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Stuart |
|
|
|
Amanda |
Schwartz |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2022 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Food & Drug Administration (FDA)
S 289/HR 869 RISE Act - emergency funding for the NIH
S 2187 - National Biomedical Research Act-
H.R. 5394- Meaningful Access to Federal Health Plan Claims Data Act of 2021 -ensures meaningful access to claims data by clinician-led clinical data registries
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Palmer |
|
|
|
Amanda |
Schwartz |
|
|
|
Kristine |
Rufener |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |